Hemophilia B Pipeline 2025

DelveInsight's "Hemophilia B Pipeline Insight 2025" report delivers extensive analysis on over 15 companies and more than 20 pipeline drugs in the Hemophilia B treatment arena. It includes thorough profiles of Hemophilia B pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Hemophilia B pipeline therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Discover the newest medications and treatment avenues in the Hemophilia B Pipeline. Explore DelveInsight's detailed report now! @ Hemophilia B Pipeline Outlook

Key Takeaways from the Hemophilia B Pipeline Report

• On September 3, 2025, Pfizer disclosed a long-term safety and effectiveness follow-up for individuals with Hemophilia B previously involved in the C0371005 (formerly SPK-9001-101) trial. Additionally, the company is launching a dose-escalation sub-study to assess the safety, tolerability, and pharmacokinetics of a higher dose, alongside extended safety and efficacy monitoring. Importantly, participation in this sub-study does not require prior involvement in the original C0371005 trial.

• DelveInsight's Hemophilia B Pipeline report illustrates a vibrant arena with over 15 active contributors developing more than 20 pipeline treatments for Hemophilia B care.

• The prominent Hemophilia B Companies include Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis, and others.

• Promising Hemophilia B Therapies include REGV131, LNP1265, APVO101, SPK-9001, ANB-002, Benefix, IB1001, marstacimab, and others.

Gain insights into Hemophilia B Clinical Trials, emerging treatments, and key companies via DelveInsight @ Hemophilia B Treatment Drugs

Hemophilia B Emerging Drugs Profile

• BBM-H901: Belief Biomed BBM-H901 is intended for preventive treatment of bleeding in adults with hemophilia B. BBM-H901 aims to restore the production of factor IX (FIX), the blood-clotting protein that is defective or absent in individuals with hemophilia B, by introducing a functional version of the F9 gene to liver cells, the primary sites of clotting factor production. Gene therapy elements are transported to liver cells via a modified, safe adeno-associated virus (AAV) acting as a carrier. The gene therapy is administered as a single intravenous infusion. The drug BBM-H901 is in Phase III clinical trials for hemophilia B treatment.

• ISU304: ISU ABXIS ISU304 (Dalcinonacog alfa, DalcA) is an engineered recombinant Factor IX protein for preventive care of patients with Hemophilia B, resulting from a lack of coagulation FIX. It is formulated for subcutaneous administration and reaches standard FIX activity levels to avert bleeding in hemophilia B patients. Existing approved protein replacement therapies for hemophilia B depend on intravenous delivery. With subcutaneous administration, ISU304 is anticipated to enhance patient quality of life and treatment ease. The drug is in Phase II clinical trials for hemophilia B.

• TU7710: TiumBio TU7710 is a bypassing agent for individuals with neutralizing antibodies, featuring an extended half-life 6~7 times longer than traditional options via transferrin fusion gene recombination technology. TU7710 is poised to significantly enhance convenience and quality of life for hemophilia patients with neutralizing antibodies. The drug is currently in Phase I clinical trials for Hemophilia B.

The Hemophilia B Pipeline Report Provides Insights into

• The report furnishes comprehensive details on organizations advancing therapies for Hemophilia B, including the total treatments each company is developing.

• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Hemophilia B management.

• Hemophilia B Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.

• Hemophilia B Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.

• Comprehensive review of partnerships (corporate alliances and academic collaborations), licensing deals, and funding information to drive future growth in the Hemophilia B market.

Explore innovative treatments and clinical trials in the Hemophilia B Pipeline. Obtain DelveInsight's detailed report today! @ Hemophilia B Drugs

Hemophilia B Companies Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis, and others.

Hemophilia B pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral

• Intravenous

• Subcutaneous

• Parenteral

• Topical

Hemophilia B Products have been categorized under various Molecule types such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Learn about emerging Hemophilia B drugs, pipeline advancements, and key companies with DelveInsight's expert analysis @ Hemophilia B Market Drivers and Barriers

Scope of the Hemophilia B Pipeline Report

• Coverage- Global

• Hemophilia B Companies- Shanghai Vitalgen BioPharma, Belief BioMed, TiumBio, Jiangsu Gensciences, Centessa Pharmaceuticals, Takeda, Sanofi, GC Biopharma Corp, Equilibra Bioscience LLC, Regeneron Pharmaceuticals, ISU Abxis, and others.

• Hemophilia B Therapies- REGV131, LNP1265, APVO101, SPK-9001, ANB-002, Benefix, IB1001, marstacimab, and others.

• Hemophilia B Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Hemophilia B Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's comprehensive Hemophilia B Pipeline report now! @ Hemophilia B Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction

2. Executive Summary

3. Hemophilia B: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Hemophilia B - DelveInsight's Analytical Perspective

7. Late Stage Products (Phase III)

8. BBM-H901: Belief Biomed

9. Drug profiles in the detailed report.....

10. Mid Stage Products (Phase II)

11. ISU304: ISU ABXIS

12. Drug profiles in the detailed report.....

13. Early Stage Products (Phase I)

14. TU7710: TiumBio

15. Drug profiles in the detailed report.....

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report.....

19. Inactive Products

20. Hemophilia B Key Companies

21. Hemophilia B Key Products

22. Hemophilia B - Unmet Needs

23. Hemophilia B - Market Drivers and Barriers

24. Hemophilia B - Future Perspectives and Conclusion

25. Hemophilia B Analyst Views

26. Hemophilia B Key Companies

27. Appendix

About Us

DelveInsight is a premier market research and consulting firm focused on healthcare, offering high-quality intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us 

Kanishk

kkumar@delveinsight.com